	US 11,992,509 B2
	Composition for prevention or treatment of neurodevelopmental disorder, neurologic diseases, or psychiatric diseases comprising extracellular vesicles derived from Micrococcus luteus
Yoon-Keun Kim, Paju-Si (KR)
Assigned to MD HEALTHCARE INC., Seoul (KR)
Filed by MD HEALTHCARE INC., Seoul (KR)
Filed on Dec. 27, 2021, as Appl. No. 17/646,143.
Claims priority of application No. 10-2020-0184337 (KR), filed on Dec. 28, 2020.
Prior Publication US 2022/0202878 A1, Jun. 30, 2022
Int. Cl. A61K 35/74 (2015.01); A61P 25/28 (2006.01)

CPC A61K 35/74 (2013.01) [A61P 25/28 (2018.01)]

5 Claims

1. A method for alleviating or treating symptoms of a degenerative brain neurologic disease in a subject in need thereof, comprising administering a composition comprising vesicles derived from Micrococcus luteus as an active ingredient to the subject having the symptoms,

wherein the disease is mediated by a NLR family pyrin domain containing 3 inflammasome (NLRP3 inflammasome),

wherein the composition suppresses NLRP3 inflammasome formation,

wherein the alleviating or treating symptoms is selected from the group consisting of suppression of progression of short-term and long-term cognitive impairments, restoration of spatial perceptual learning or memory, restoration of memory ability, suppressing memory ability loss induced by abnormal beta-amyloid (Aβ) protein, suppression of accumulated Aβ plaque, induction of neurogenesis, and protection of microstructure of dendrites to improve intercellular integrity, and

wherein the degenerative brain neurologic disease is one or more diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and epilepsy.